SPONSORSHIP OPPORTUNITIESThe sponsorships program is a great opportunity to reach many of the ECC delegates and deliver the knowledge and awareness of your product or service. There are a number of sponsorship packages available. The ECC Congress is planned as a hybrid event but we are also prepared for a traditional on-site form. Detailed information can be found in below documents:
Sponsor's offer ECC 2021 English
Oferta sponsorska ECC2021 w języku polskim
For further information please contact:
Below we would like to present you the 43rd Europan Congress of Cytology Sponsors!
Lunch Symposium Sponsor - Zhiwei Morphogo
Lunch Symposium - Tuesday, 5th October, 13:15 - 14:15 (Poland time zone)
Morphogo is a high-tech company specializing in the application of artificial intelligence (AI) technology to cytopathological diagnosis. With technological innovation as the core, the company cooperates with renowned medical institutions around the world to build an international multi-center scientific research framework. The AI-aided bone marrow cytomorphology analysis and diagnosis system independently developed by Morphogo is a breakthrough in the application of AI technology to the field of bone marrow aspirate smear morphology examination, significantly reducing the labor intensity of morphology experts and improving the objectivity and consistency of morphology examination.
Now, the company is actively expanding product lines including analysis of peripheral blood, urine, pleuroperitoneal fluid and cerebrospinal fluid. The company aims to use a fully automated digital slide generation system and artificial intelligence to assist in changing the conventional cytopathological analysis and diagnosis, and create a new pathological environment driven by the concept of “to revolutionize conventional medical examination with artificial intelligence”.
AI-Aided Bone Marrow Cytomorphology Analysis and Diagnosis System (Morphogo) is developed by Hangzhou Zhiwei Information&Techonlogy Company. The system automatically digitizes bone marrow smears by fine whole slide scanning under 40x objective, and it identifies and classifies nucleated cells in the field of view under 100x oil lens utilizing artificial intelligence. It is expected to realize automatic classification of 269 types of nucleated cells and multiple statistical methods such as calculating cell percentages by ANC (all nucleated cells), WBC (white blood cells), NEC (non-erythroid cells), or cell linage. It is the world’s leading medical device for cytopathology and bone marrow cell morphology.
This device has been tested in 19 well-known medical institutions both domestic and overseas. The accuracy of cell classification reaches 90%. At present, it has obtained a medical device manufacturing and sales license from PMDA in Japan. In Europe, it has obtained CE-mark. In China, clinical trials of the NMPA medical device registration had been done by the end of 2020, and the approval is expected to be achieved in the first half-year of 2021.